Skip to main content

Rigel Pharmaceuticals Inc

RIGL
Exchange
Nasdaq
Industry
Pharmaceutical Preparations
SEC CIK
0001034842

No open-market purchases or sales by Rigel Pharmaceuticals Inc insiders were filed in the last 90 days; 155 institutions reported holding it in 13F filings for Q2 2026, worth $640.4M in total; no superinvestor holds it.

13F holders, Q1 2026

Institutional positions in Rigel Pharmaceuticals Inc as of Mar 31, 2026. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works

Institutional holders
159
−31 vs. Q4 2025
Shares held
16.0M
+976.7K (+6.5%) vs. Q4 2025
Total value
$432.8M
−$210.2M (−32.7%) vs. Q4 2025
New holders
16
73 more added
Sold out
47
49 more reduced

4 institutions that held it in Q4 2025 haven't filed for Q1 2026 yet. Not filing isn't selling, so they aren't counted as sold out or in the changes above.

Compare with Q4 2025: new holders, sold out and not filed yet

Holders and value by quarter

Institutions reporting RIGL on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.

Institutional holdersQ1 2026: 159 institutions
Q1 2021: 152 institutionsQ2 2021: 160 institutionsQ3 2021: 163 institutionsQ4 2021: 162 institutionsQ1 2022: 163 institutionsQ2 2022: 135 institutionsQ3 2022: 138 institutionsQ4 2022: 118 institutionsQ1 2023: 125 institutionsQ2 2023: 118 institutionsQ3 2023: 106 institutionsQ4 2023: 113 institutionsQ1 2024: 117 institutionsQ2 2024: 91 institutionsQ3 2024: 93 institutionsQ4 2024: 122 institutionsQ1 2025: 123 institutionsQ2 2025: 126 institutionsQ3 2025: 169 institutionsQ4 2025: 194 institutionsQ1 2026: 159 institutionsQ2 2026: 155 institutions
Value heldQ1 2026: $432.8M
Q1 2021: $493.1MQ2 2021: $614.5MQ3 2021: $499.6MQ4 2021: $365.9MQ1 2022: $405.7MQ2 2022: $157.2MQ3 2022: $150.3MQ4 2022: $163.1MQ1 2023: $148.6MQ2 2023: $142.7MQ3 2023: $114.8MQ4 2023: $154.5MQ1 2024: $164.3MQ2 2024: $85.4MQ3 2024: $192.6MQ4 2024: $203.0MQ1 2025: $250.2MQ2 2025: $260.2MQ3 2025: $425.6MQ4 2025: $690.5MQ1 2026: $432.8MQ2 2026: $640.4M
Institutions holding RIGL and their total value by quarter
QuarterHoldersValue
Q2 2026155$640.4M
Q1 2026159$432.8M
Q4 2025194$690.5M
Q3 2025169$425.6M
Q2 2025126$260.2M
Q1 2025123$250.2M
Q4 2024122$203.0M
Q3 202493$192.6M
Q2 202491$85.4M
Q1 2024117$164.3M
Q4 2023113$154.5M
Q3 2023106$114.8M
Q2 2023118$142.7M
Q1 2023125$148.6M
Q4 2022118$163.1M
Q3 2022138$150.3M
Q2 2022135$157.2M
Q1 2022163$405.7M
Q4 2021162$365.9M
Q3 2021163$499.6M
Q2 2021160$614.5M
Q1 2021152$493.1M

Institutions, Q1 2026

Shares, value and share of portfolio for each institution holding Rigel Pharmaceuticals Inc; share changes are against Q4 2025.

Institutions holding RIGL in Q1 2026
InstitutionSharesValue% of portfolioChange in sharesAction
Aster Capital Management (DIFC) Ltd0$00.00%−133−100.0%Sold out
Caitong International Asset Management Co., Ltd0$00.00%−125−100.0%Sold out
C M Bidwell & Associates Ltd0$00.00%−115−100.0%Sold out
Chilton Capital Management LLC0$00.00%−47−100.0%Sold out
Daiwa Securities Group Inc.0$00.00%−40−100.0%Sold out
SRS Capital Advisors, Inc.0$00.00%−1−100.0%Sold out
Vanguard Group Inc––––Not filed
Brandywine Global Investment Management, LLC––––Not filed
CIBC Private Wealth Group, LLC––––Not filed
Motiv8 Investments LLC––––Not filed